Live

Mitochondria, potential new therapeutic targets in pancreatic cancer - CRCM PhD Day 2021 will take place on May 28 2021 - La cycline A2, qui maintient l'homéostasie du côlon, est un facteur de pronostic dans le cancer colorectal -

02 2019 Therapeutic drug monitoring

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.

Authors

Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F

Summary

Therapeutic drug monitoring of carboplatin is based on its unbound clearance (CLU) determined by Bayesian analysis on unbound (U) concentrations. However, the ultrafiltration of plasma samples presents technical and time constraints. Therefore, this study aims to estimate CLU using total plasma (P) concentrations.

Read the article